B. Ewald

发表

Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease

W. Plunkett, D. Sampath, Alma Zecevic, 2011, Clinical Cancer Research.

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation

W. Plunkett, D. Sampath, B. Ewald, 2007, Molecular Cancer Therapeutics.

Nucleoside analogs: molecular mechanisms signaling cell death

W. Plunkett, D. Sampath, B. Ewald, 2008, Oncogene.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia

R. Garzon, W. Plunkett, J. Blachly, 2016, Clinical Cancer Research.

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.

G. Dharmadhikari, F. Lang, A. Patiño-García, 2022, The New England journal of medicine.

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

K. Aldape, W. Yung, G. Fuller, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.

G. Calin, C. Taccioli, V. Puduvalli, 2009, Blood.

ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

W. Plunkett, D. Sampath, B. Ewald, 2008, Cancer research.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

T. Cloughesy, H. Colman, M. Daras, 2020 .

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Andreas Engert, Arnold S. Freedman, Martin J. S. Dyer, 2014, British journal of haematology.

ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

T. Cloughesy, H. Colman, M. Daras, 2018, Neuro-Oncology.

Abstract 6713: Oncolytic adenoviruses expressing immune modulators enhance tumor cell killing in human cancer 3D microtumor models

B. Ewald, J. Robbins, Laura K Springgay, 2020 .

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

M. Dyer, A. Freedman, D. Heo, 2014, British journal of haematology.